NCT07770360尚未招募不适用
Prospective, Parallel Clinical Performance Study of the INSTI® and TruPlex Rapid Blood Typing Platforms
bioLytical Laboratories0 个研究点目标入组 2,500 人开始时间: 2026年8月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 2,500
- 主要终点
- Clinical performance of the INSTI® and TruPlex Rapid Blood Typing Tests for ABO (A, B, AB, and O) and RhD blood type detection
研究概览
简要总结
CLS-019A is a prospective, multi-site, parallel clinical performance study. Each enrolled subject is tested on both investigational devices in parallel within a single study visit, yielding paired INSTI® and TruPlex results from matched capillary fingerstick and EDTA-VWB samples.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects will be enrolled in the Main Cohort if they meet all of criteria IC.1 through IC.
- •Subjects will be enrolled in the Rare-Phenotype Cohort if they meet all of criteria IC.1 through IC.7:
- •Subject is 18 years of age or older at the time of enrollment.
- •Subject is able to provide written informed consent prior to any study-related procedures.
- •Operator or study staff is able to obtain required data to complete the subject's Enrollment Questionnaire.
- •Subject is able and willing to complete all required study procedures on the allocated testing day.
- •Subjects is able to speak/read/write in English or Spanish.
- •Subjects is willing to provide:
- •Two (2) capillary fingerstick whole blood samples, and
- •Venous whole blood samples collected by venipuncture (approximately 10 mL), as required for the study. And
- •If required, a maximum of two (2) further fingerstick whole blood samples in the case that the initial INSTI and/or TruPlex test results are invalid.
- •Additional Inclusion Criterion for Rare-Phenotype Cohort Enrollment:
- •Subject has a previously documented rare ABO subgroup or RhD variant phenotype.
排除标准
- •Subjects will be excluded from the study if they meet any of the following criteria:
- •Subject has known bleeding disorder or any other medical condition that, in the opinion of the Investigator or Operator, contraindicates fingerstick or venipuncture.
- •Subject has received a blood transfusion within the past 120 days.
- •Subject is currently using therapeutic anticoagulants (e.g., warfarin, heparin, or direct oral anticoagulants [DOACs]) that, in the opinion of the Investigator or Operator, may interfere with sample collection or test performance.
- •Subject has any condition which, in the opinion of the Investigator or Operator, would:
- •Place the participant at undue risk,
- •Interfere with completion of study procedures,
- •Compromise the informed consent process, or
- •Bias the interpretation of study results. Examples include, but are not limited to: intoxication, acute illness, visible distress, or inability to understand study procedures.
结局指标
主要结局
Clinical performance of the INSTI® and TruPlex Rapid Blood Typing Tests for ABO (A, B, AB, and O) and RhD blood type detection
时间窗: 6 months
To evaluate the clinical performance (PPA and NPA) of the INSTI® and TruPlex Rapid Blood Typing Tests for ABO (A, B, AB, and O) and RhD blood types through detection of A, B, and RhD antigens using both capillary fingerstick and EDTA venous whole blood (VWB) samples. Performance will be determined by comparing the results of each investigational device with reference tests for ABO and RhD status.
次要结局
- INSTI® and TruPlex Rapid Blood Typing Test Invalid Rate(6 months)
研究者
相似试验
尚未招募
3 期
Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT07477808Hunan Province Tumor Hospital116
招募中
Phase 3 4
To check bond reliability of peek coping with ceramic layering material compared to peek coping layered with compositeCTRI/2024/03/063769Maulana Azad Institute of Dental Sciences30
尚未招募
4 期
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer PatientsNCT07358520Fudan University40
进行中（未招募）
不适用
Clinical Performance Evaluation of RDX-Aneurysm for Detecting Intracranial Aneurysms on TOF-MRAIntracranial AneurysmNCT07655635Taipei Medical University Shuang Ho Hospital550
尚未招募
2 期
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal CancerNCT07446387Jiangsu Cancer Institute & Hospital70